Development and psychometric properties of short form of central sensitization inventory in participants with musculoskeletal pain: A cross-sectional study

Tomohiko Nishigami¹*, Katsuyoshi Tanaka², Akira Mibu¹, Masahiro Manfuku³, Satoko Yono², Akihito Tanabe²

¹ Department of Nursing and Physical Therapy, Konan Woman's University, Kobe, Hyogo, Japan, ² Department of Rehabilitation, Tanabe Orthopaedics, Osaka, Osaka, Japan, ³ Department of Rehabilitation, Breast Care Sensyu Clinic, Osaka, Kishiwada, Japan

* t-nishi@konan-wu.ac.jp

Abstract

Background

The central sensitization inventory (CSI) comprises 25 items and is commonly used to measure somatic and emotional symptoms related to central sensitization symptoms. CSI was developed as an easy-to-administer screening instrument for patients at high risk of developing central sensitization in whom it was essential to quickly evaluate the condition. The purpose of the present study was to develop a short form of CSI and evaluate its psychometric properties using a contemporary approach called Rasch analysis.

Methods

A total of 505 patients with musculoskeletal disorders were recruited in this study. The CSI, pain intensity, pain interference, and the health-related quality of life (QOL) were evaluated for each participant. The original CSI items were consecutively analyzed using the Rasch model. Successive Rasch analyses were performed until a final set of items satisfied the model fit requirements. We also analyzed the psychometric properties of the original and short forms of CSI.

Results

Four consecutive Rasch analyses identified the removable items. Finally, the shortest questionnaire obtained that maintained the correct psychometric properties based on the Rasch model contained only 9 items (CSI-9). Rasch analysis showed that the CSI-9 had acceptable internal consistency, exhibited unidimensionality, had no notable differential item functioning, and was functional on the category rating scale.
Conclusions
The nine-item short form of CSI has acceptable psychometric properties and is suitable for use for patients with musculoskeletal pain. Thus, the CSI-9 can be used as a brief instrument to evaluate central sensitization.

Introduction
The International Association for the Study of Pain defines central sensitization (CS) as an increased responsiveness of nociceptive neurons in the central nervous system to normal or subthreshold afferent input [1]. Several systematic reviews demonstrate that CS plays a significant role in the treatment of patients with osteoarthritis [2], shoulder pain [3], whiplash [4], fibromyalgia [5], and tendinopathy [6]. The Central Sensitization Inventory (CSI) was developed as a screening instrument for CS-related symptoms [7]. The scale comprises 25 items related to the assessment of health-related symptoms that are common to central sensitivity syndromes (CSS), such as restless leg syndrome, chronic fatigue syndrome, fibromyalgia, and temporomandibular joint disorder. Confirmatory factor analysis revealed that a bifactor mode containing one general factor and four orthogonal factors (physical symptoms, emotional distress, headache/jaw symptoms, and urological symptoms) fits the CSI structure better than the unidimensional and the 4-factor models [8].

The CSI total scores have been shown to distinguish between patients with chronic pain and control subjects [9, 10]. A higher CSI score is associated with pain-related outcomes [10, 11] and increase in levels of brain-derived neurotrophic factor [12], which contributes to both induction and maintenance of CS [13], and predicts poor long-term postoperative outcomes [14,15].

CSI has been translated into many languages and has been validated by a variety of practitioners[12, 16–21]. A systematic review revealed that CSI has strong psychometric properties and therefore could be a clinically useful measurement instrument [22]. While CSI comprises 25 items and can be used as a psychometric instrument, it is easier to use in clinical settings if it is shorter. Alternative questionnaires such as a shorter version of pain catastrophizing scale [23–25], pain beliefs and coping strategies [26–28], and pain-related self-efficacy [29] were developed to facilitate a quick screening and to reduce the participant’s burden. This short version of the questionnaire is also preferable because many health professionals have limited time with patients in a clinical setting. CSI was developed as an easy-to-administer screening instrument for patients at higher risk of developing CS [7] in whom it was essential to quickly evaluate the condition. Thus, a brief questionnaire on CSI has the potential to be clinically useful, to be time efficient, and to reduce patient burden in both clinical and research environments. However, it has been noted that shorter questionnaires risk sacrificing reliability. Therefore, short-form measures must be shown to have an acceptable level of reliability and validity.

The Rasch model [30], which is included in the item response theory, can be used to estimate the item or ability parameters and is a way to analyze responses to questionnaires with the goal of improving measurement accuracy and reliability. It is often used to reduce the items covered in questionnaires [31–36]. This model constructs a line of measurement with the items placed hierarchically [37, 38], which permits identification of redundant items to be omitted from the original questionnaire. The present study aimed to develop a short form of CSI and evaluate its psychometric properties.
Methods

Participants

Individuals aged between 20 and 80 years were consecutively recruited and screened by orthopedists to receive physical therapy from an orthopedic clinic. Those with acute (pain that lasts less than 3 months) or chronic (pain that lasts for at least 3 month) musculoskeletal pain disorders (lower back pain, neck pain, knee pain, ankle pain, and/or hand pain) were included. All participants underwent X-ray examination before receiving physical therapy. At the screening stage by orthopedists, participants with fracture, sprain, cancer, multiple sclerosis, brain or spinal cord injury, history of stroke, or history of psychiatric disease (e.g., schizophrenia, bipolar disorder, or somatoform disorder) as diagnosed by a psychiatrist were excluded.

All evaluations were performed before physical therapy. Of the initial sample of 510 participants, 5 participants were excluded because they did not complete all the items in the questionnaires. A total of 505 individuals were included; all these patients were Japanese. Their characteristics are summarized in Table 1. Patients with musculoskeletal disorders were distributed as follows: 187 patients (37.0%) with lower back pain, 89 (17.6%) with neck pain, 84 (16.6%) with shoulder pain, 82 (16.2%) with knee pain, 42 (8.3%) with ankle pain, and 21 (4.1%) with hand pain. Of all the participants, 333 (65.9%) were women with mean ± standard deviation (SD) age of 52.4 ± 15.1 years and mean ± SD pain duration of 22.6 ± 57.4 weeks.

Ethical approval was obtained from the Institutional Ethics Committee of Konan Woman’s University. Written informed consent was obtained from all the participants before the study, and the study was conducted in accordance with the tenets of the Declaration of Helsinki.

Procedures

All participants were assessed for demographic data (age, gender, height, and weight), pain duration, CSI, health-related quality of life (QOL), pain intensity, and pain interference. CSI-J consists of Parts A and B. Part A consists of a 25-item self-report questionnaire designed to assess health-related symptoms that are common to CSS. Each item is rated on a 5-point Likert-type scale, with total scores ranging from 0 to 100. Part B (which is not scored) asks the participants whether one or more specific disorders, including seven separate CSSs, have been diagnosed previously (restless leg syndrome, chronic fatigue syndrome, fibromyalgia, temporomandibular joint disorder, migraine or tension headaches, irritable bowel syndrome, multiple chemical sensitivities, neck injury (including whiplash], anxiety or panic attacks, and depression).

Health-related QOL was measured using the EuroQol 5-dimension (EQ-5D) instrument [39]. EQ-5D was developed as a non-disease specific standardized instrument, which could be used to complement existing health-related QOL measure [40, 41]. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three grades (no problems, some problems, and extreme problems), which

| Characteristics          | Mean (SD) or N (%) | Range       |
|--------------------------|--------------------|-------------|
| Gender (female)          | 333 (65.9%)        |             |
| Age (years)              | 52.4 (15.1) 20–80  | 20–80       |
| Height (cm)              | 161.7 (8.7)        | 137–191     |
| Weight (kg)              | 59.5 (12.3)        | 35–118      |
| Duration of pain (week)  | 22.6 (57.4)        | 1–528       |

https://doi.org/10.1371/journal.pone.0200152.t001
generates a single index value for each health state. These values are numbers on a scale where 1 refers to full health and 0 refers to death.

Pain intensity and interference were measured using the Brief Pain Inventory (BPI) [42, 43]. BPI comprises four pain intensity and seven pain interference items. These items are rated using a scale of 0–10, where 0 = no pain and 10 = worst possible pain. Based on the values obtained, individual pain intensity and interference scores were evaluated by calculating the mean. The validation and clinical utility of BPI has been evaluated for several disorders [44–46].

### Development of a short version of CSI

**Rasch analysis.** The original CSI was consecutively analyzed using the Rasch model by Winsteps software (v3.90.2, Chicago, Illinois). Chi-square fit statistics were used to determine how well each CSI item contributed to total CSI scores [47]. The most commonly used chi-squares are known as outfit and infit, which are reported as mean squares (in logits) [48]. Rasch analysis examines the predictability of the data when assessing item quality directly using the mean-square statistics. Excessively large-fit residuals (>1.3 logits) indicate a large difference between the expected and observed performance of an item [47], and may indicate that the item is assessing a construct other than what it was intended to assess. In contrast, excessively small-fit residuals (<0.7 logits) indicate items that behave too predictably [48]. Successive Rasch analyses were performed until a final set of items satisfied the model fit requirements.

**Psychometric properties of a short version of CSI.** We investigated the psychometric properties of the original and shortened questionnaires, and compared the following components:

**Category order.** We assessed category order to ensure the Likert scale functioned as expected. The CSI has five response categories (0 = Never, 1 = Rarely, 2 = Sometimes, 3 = Often, 4 = Always). Category probability curves, and average measure and category fit statistics (infit and outfit) were used to explore rating scale functioning. Fit statistics are recommended to be between 0.6 and 1.4 [49, 50]. Moreover, in a well-functioning rating scale, each curve has a distinct peak and 4 clear thresholds that represent the point at which the likelihood of endorsing one category is equal to that of endorsing the next. Disordered thresholds can occur if a category is underutilized or respondents use the categories in an unexpected manner (e.g., respondents cannot differentiate between the categories). In addition, the item characteristic curve (ICC) was plotted. The item is more discriminating where the ICC is steeper, and less discriminating where the ICC is flatter.

**Targeting.** Scale-to-sample targeting was made by comparing person locations from the sample with item locations of the scale. Their means should be close to 0 logits. In addition, we investigated targeting by visualizing the person-item map and comparing the means of the items and person measures. This was analyzed by plotting the person-item location threshold distribution graph with distributions of persons on the top half of the graph and item thresholds at the bottom half of the graph. Good targeting means that the distributions of persons and distributions of item thresholds match visually.

**Internal consistency.** Winsteps provides a person reliability index and Cronbach’s alpha as indicators of internal consistency [51] and both should exceed 0.7 [52]. McDonald’s Omega was also calculated using Mplus 8 (Los Angeles, CA, United States).

**Unidimensionality.** We intended to summate the CSI to provide an overall measure of CS-related symptomology. Individual items should share this unidimensional construct yet be sufficiently different to warrant their inclusion. Assessment of fit evaluates unidimensionality by identifying items that function unexpectedly. The principal component analysis of residuals
(PCA) identifies unexpected clusters of items suggestive of a secondary dimension that could threaten measurement of the primary dimension. The PCA residual correlation matrix was visually inspected to identify clusters of items that would be suggestive of a second dimension. An eigenvalue greater than 2.0 for the PCA of residuals suggests a second dimension [53]. Response dependency between the items was examined by inspecting the residual correlation matrix [52] for pairs of items with correlations exceeding 0.4 [54–55].

The dimensionality of both versions was also explored using exploratory structural equation modeling (ESEM) with geomin oblique rotation in Mplus 8. We tested various models: from a one-factor model to a five-factor model in the CFI-25 and from a one-factor model to a two-factor model in the CFI-9. A minimum cutoff of 0.95 for Comparative Fit Index (CFI), a maximum cutoff of 0.08 for Root Mean Square Error of Approximation (RMSEA), and a maximum cutoff of 0.08 for Standardized Root Mean Square Residual (SRMR) were considered as indicative of acceptable fit [56–58]. Models with smaller values of Akaike information criterion (AIC) and Bayesian information criterion (BIC) are preferred to those with higher AIC and BIC values.

**Person fit.** Participants with outfit residuals greater than 1.5 logits were examined to determine the reason for poor fit. They were compared with those who fit the model using Fisher’s exact test [59] of significance (for gender) or the Mann-Whitney U test (for age, pain intensity, pain duration, and CSI). Response strings of misfitting participants were analyzed to identify patterns in their responses.

**Differential item functioning (DIF).** Items should function in a similar manner for all people of similar levels of agreeability. We assessed for DIF across 5 subgroups: gender, age (≤60, >60 years), pain intensity from BPI (≤5, >5), pain duration (≤12, >12 month), and pain interference from BPI (median split: ≤2.75, >2.75). DIF was tested using a Mantel-Haenszel chi-square test with significance level set at $p = 0.01$ for each item. Item bias was explored if an item yielded a significant difference of greater than 0.5 logits between subgroups [60].

**Test-retest reliability.** CSI reliability was assessed using scores obtained from a second round of the questionnaire administered to participants within 2 weeks of the first questionnaire completion. An intraclass correlation coefficient (ICC) 2-way mixed model with absolute agreement was used to determine measurement reliability. ICC$_{3,1}$ values 0–0.40 were considered to indicate fair reliability, 0.41–0.60 moderate reliability, 0.61–0.80 substantial reliability, and 0.81–1.00 almost perfect reliability [61].

**Relationship to clinical status.** Correlation analysis was evaluated using the Statistical Package for Social Sciences Version 25 (IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.). Data distribution was tested for homoscedasticity using the Kolmogorov-Smirnov test. A series of correlations was performed examining the relationships between the original and the short form of CSI total score and pain intensity, interference, and QOL. These correlations were investigated with Spearman’s correlation coefficient.

In addition, the correlation between the original and the short form of CSI total score was investigated by calculating the ICC$_{3,1}$ and the 95% confidence interval for agreement. ICC$_{3,1}$ values 0–0.40 were considered to indicate fair reliability, 0.41–0.60 moderate reliability, 0.61–0.80 substantial reliability, and 0.81–1.00 almost perfect reliability [61].

**Short form of CSI total score groupings by CSS diagnoses.** Five severity levels of the original CSI (subclinical = 0–29, mild = 30–39, moderate = 40–49, severe = 50–59, and severe = 60–100) were recommended to evaluate symptom severity or assess clinical changes in response to treatment [58]. To determine the level of CSI severity in the shorter version of CSI, the difference in shorter version of CSI scores was compared with the number of CSS (0 vs. 1 vs. 2 vs. 3+) using one-way analysis of variance (ANOVA) and Tukey post-hoc analysis as
well as the original CSI did [62]. CSS diagnoses were determined from subject self-report on CSI part B. P values of \(< 0.05\) were considered statistically significant.

The differences in age, pain duration, pain intensity, pain interference, and health-related QOL were also compared with the shortened CSI severity level group using ANOVA and Tukey post-hoc analysis. Gender was compared with the shortened CSI severity level group using the chi-squared test. We adjusted alpha to 0.008 because we undertook six separate analyses.

**Results**

Table 2 provides a summary of the clinical profile of all participants. Of 505 participants, 377 (74.6\%) participants had acute pain and 128 (25.4\%) participants had chronic pain.

**Development of the shortened questionnaire**

Four consecutive Rasch analyses identified the items that could be removed from the questionnaire (Table 3). Finally, the shortest questionnaire that maintained correct psychometric properties based on the Rasch model was obtained. It contained only 9 items (CSI-9). The CSI-9 items include: 1. Unrefreshed in morning; 2. Muscles stiff/achy; 3. Pain all over body; 4. Headaches; 5. Do not sleep well; 6. Difficulty concentrating; 7. Stress makes symptoms worse; 8. Tension in neck and shoulders; 9. Poor memory. (S1 Table). Table 4 summarizes the fit statistics for the original CSI (CSI-25) and CSI-9.

**Table 2. Clinical profiles.**

| Clinical profiles                  | Mean (SD) | Range   |
|-----------------------------------|-----------|---------|
| Pain intensity (BPI, 0–10)        | 2.9 (1.7) | 0–9.75  |
| Pain interference (BPI, 0–10)     | 2.5 (2.1) | 0–10.0  |
| Health-related QOL (EQ-5D, 0–1)   | 0.71 (0.11) | 0.334–1 |
| Central sensitization (CSI-25, 0–100) | 21.4 (12.9) | 0–80 |
| Central sensitization (CSI-9, 0–36) | 10.9 (5.8) | 0–32 |

EQ-5D: EuroQol 5-dimension, CSI: Central sensitization inventory, BPI: Brief Pain Inventory.  
https://doi.org/10.1371/journal.pone.0200152.t002

**Table 3. Item selection from Rasch analysis.**

| Item removed | 1st Round | 2nd Round | 3rd Round | 4th Round Final set |
|--------------|-----------|-----------|-----------|---------------------|
| Item remaining |           |           |           |                     |
| Emotional distress | 15 | 15 | 15 | 15 |
| 9, 11, 21, 22, 23, 25 | 9, 11, 21, 22, 23 | 9, 22, 23 | 9, 23 |
| Muscle problem | 2, 18 | 2, 18 | 2, 18 | 2, 18 |
| Headache/jaw symptoms | 4, 10, 19 | 10 | 10 | 10 |
| 1, 8, 12 | 1, 12 | 1, 12 | 1, 12 |
| Not loading | 3, 6, 7, 8, 13, 14, 20 | 3, 6, 13, 14 | 3, 13 | 13 |

Information about the number of items addressing each content in the CSI-25 and CSI-9  
https://doi.org/10.1371/journal.pone.0200152.t003
Psychometric assessment of CSI

Targeting. The sample was not well targeted by both versions of CSI. The average person endorsability of CSI-25 and CSI-9 (mean ± SD logits) were -1.42 ± 0.91 and -1.09 ± 1.11, respectively. The item endorsability averages of CSI-25 and CSI-9 (mean ± SD logits) were 0 ± 0.72 and 0 ± 0.79, respectively. Visually, the shifting of person agreeability of CSI-25 and CSI-9 to the left when compared with item endorsability indicated that participants with low levels of central sensitization were not well targeted by the scale (Fig 1).

In CSI-25 and CSI-9, 4 (0.7%) and 7 participants (1.3%), respectively, scored zero for all the items. None of the participants for CSI-25 and CSI-9 scored full points on all items.

Category order. The average agreeability measures of the respondents advanced as expected across the rating scale categories in both CSI-25 and CSI-9, and there was neither excessive positive nor negative fit statistics in CSI-9, suggesting the category structure is adequate, but, in CSI-25, there was no excessive outfit statistics (Table 5).

Category 4 in CSI-25 was underutilized, which suggests the respondents experienced difficulty differentiating "often" from "always" (Fig 2A). Each category in CSI-9 has a distinct peak suggesting the categories are not disordered. That is, the step calibrations (the thresholds

| Item | Measure (Logits) | SE | Infit (mnsq) | Outfit (mnsq) | Measure (Logits) | SE | Infit (mnsq) | Outfit (mnsq) |
|------|-----------------|----|-------------|--------------|-----------------|----|-------------|--------------|
| 2    | -1.53           | 0.04| 0.94        | 1.03         | -1.27           | 0.05| 0.97        | 1.01         |
| 18   | -1.46           | 0.04| 1.19        | 1.20         | -1.18           | 0.05| 1.14        | 1.12         |
| 1    | -1.10           | 0.05| 0.72        | 0.72         | -0.73           | 0.05| 0.70        | 0.71         |
| 12   | -0.50           | 0.05| 0.85        | 0.84         | 0.03            | 0.06| 0.94        | 0.91         |
| 8    | -0.50           | 0.05| 0.67        | 0.65         | -               | -   | -           | -            |
| 25   | -0.45           | 0.05| 1.40        | 1.43         | -               | -   | -           | -            |
| 5    | -0.41           | 0.05| 1.35        | 1.53         | -               | -   | -           | -            |
| 14   | 0–0.31          | 0.05| 1.26        | 1.26         | -               | -   | -           | -            |
| 10   | -0.23           | 0.05| 0.94        | 0.98         | 0.38            | 0.06| 1.05        | 1.07         |
| 17   | -0.08           | 0.05| 0.61        | 0.59         | -               | -   | -           | -            |
| 13   | -0.04           | 0.05| 0.72        | 0.66         | 0.60            | 0.06| 0.94        | 0.84         |
| 4    | -0.04           | 0.05| 1.37        | 1.45         | -               | -   | -           | -            |
| 15   | -0.04           | 0.05| 0.78        | 0.73         | 0.61            | 0.06| 1.01        | 0.98         |
| 9    | -0.02           | 0.05| 1.00        | 0.93         | 0.64            | 0.06| 1.15        | 1.05         |
| 22   | 0.01            | 0.06| 1.15        | 1.00         | -               | -   | -           | -            |
| 16   | 0.14            | 0.06| 0.65        | 0.57         | -               | -   | -           | -            |
| 21   | 0.18            | 0.06| 1.27        | 1.27         | -               | -   | -           | -            |
| 23   | 0.21            | 0.06| 0.97        | 0.98         | 0.92            | 0.07| 1.26        | 1.29         |
| 20   | 0.51            | 0.07| 1.41        | 1.25         | -               | -   | -           | -            |
| 7    | 0.52            | 0.07| 1.33        | 1.18         | -               | -   | -           | -            |
| 3    | 0.70            | 0.07| 1.22        | 0.97         | -               | -   | -           | -            |
| 19   | 0.79            | 0.07| 1.40        | 1.10         | -               | -   | -           | -            |
| 6    | 0.96            | 0.08| 1.29        | 1.25         | -               | -   | -           | -            |
| 11   | 1.13            | 0.09| 1.29        | 1.03         | -               | -   | -           | -            |
| 24   | 1.57            | 0.11| 1.37        | 0.93         | -               | -   | -           | -            |

Bold type indicates excessive item misfit.

Negative item measures indicate items that are easier to endorse, and positive measures indicate items that are more difficult to endorse. SE = standard error of measure, mnsq = mean square (chi-square based fit statistic).

https://doi.org/10.1371/journal.pone.0200152.t004
Unidimensionality. PCA of the residuals indicated that the unexplained variance of the first contrast of CSI-25 and CSI-9 was 2.2 and 1.6 eigenvalue units, respectively, indicating multidimensionality of CSI-25 and unidimensionality of CSI-9. The tested five-factor ESEM models in CSI-25 and two-factor model in the CFI-9 were the most fitted to the data (Table 6).

Internal consistency. The person reliability of CSI-25 and CSI-9 was 0.90 and 0.77, respectively. Cronbach’s alpha of CSI-25 and CSI-9 were 0.89 and 0.80, respectively. McDonald’s Omega of CSI-25 and CSI-9 were also 0.89 and 0.80, respectively. These results suggest that both versions of CSI have good internal consistency.

Table 5. Average category score thresholds, including fit statistics.

| Category score | Measure (Logits) | Infit  | Outfit | Measure (Logits) | Infit  | Outfit |
|----------------|------------------|--------|--------|------------------|--------|--------|
| 0              | -2.00            | 0.95   | 0.97   | -2.03            | 1.06   | 1.04   |
| 1              | -1.13            | 0.96   | 0.75   | -1.17            | 0.90   | 0.88   |
| 2              | -0.58            | 0.94   | 0.93   | -0.38            | 0.94   | 0.96   |
| 3              | -0.16            | 1.11   | 1.26   | 0.34             | 0.94   | 0.95   |
| 4              | 0.20             | 1.35   | 1.65   | 0.87             | 1.16   | 1.23   |

Negative item measures indicate items that are easier to endorse, and positive measures indicate items that are more difficult to endorse.

https://doi.org/10.1371/journal.pone.0200152.t005
Analysis of person fit of CSI-25 and CSI-9 identified 73 participants (14.4%) and 70 participants (13.8%) with excessive positive outfit (>1.5 logits), respectively. In CSI-25, the CSI-25 score of participants with misfit were significantly higher than those without misfit (mean difference 5.4 point, p < 0.01).

**Differential item functioning (DIF).** There was differential item functioning for age (items 10, 21, 22 and 23) in CSI-25, but there was no differential item functioning for age, gender, pain intensity, pain interference or pain duration in CSI-9.

**Test-retest reliability.** Of the participants who reported no change (the difference between first and second round of pain intensity during movement is under 10 mm) in pain intensity during the past 2 weeks (n = 100), in CSI-25 and CSI-9, there was excellent agreement between test and retest total scores, with an ICC$_{3,1}$ of 0.86 (95% confidence interval [CI], 0.80–0.9) and 0.79 (95% CI, 0.71–0.85), respectively.

**Relationship to clinical status.** The CSI-9 was significantly correlated with CSI-25 (rho = 0.91, p < 0.001) (Table 7). The CSI-25 and CSI-9 were significantly correlated with pain intensity (0.42 and 0.45, respectively, p < 0.001), pain interference (0.51 and 0.50, p < 0.001), and EQ-5D (-0.43 and -0.41, p < 0.001). The ICC$_{3,1}$ of the CSI-25 and CSI-9 was 0.69 (95% confidence interval, 0.64–0.73), suggesting substantial agreement.

**Short form of CSI total score groupings by CSS diagnoses.** Of the 505 participants, 372 (73.6%) reported 0, 96 (19.0%) reported 1, 24 (4.7%) reported 2, and 13 (2.5%) reported ≥ 3 CSS diagnoses. The CSI-9 mean score was 9.9 ± 5.5 in the no CSS group, 13.0 ± 5.0 in the 1 CSS group, 13.7 ± 6.5 in the 2 CSS group, and 20.5 ± 5.7 in the 3 or more CSS group. The CSI score in patients with no CSS was significantly lower than in those with 1, 2, and 3 or more CSS. There was no significant difference in CSI-9 total score between the 1 and 2 CSS groups.

ANOVA identified that there was consistent worsening in pain intensity, pain interference, and health-related QOL with respect to the CSI-9 severity levels (Table 8). The number of men was significantly higher in the subclinical level than that of women, whereas the number of women was significantly higher in the mild level than that of men.
Discussion

The current study aimed to develop a short form of CSI and evaluate its psychometric properties. This is the first study to develop and validate a shortened CSI. The shortened CSI was obtained by reduction of the long and well-validated questionnaires by removing selected items using Rasch analysis. Rasch analysis has been proposed as an objective and optimal method to construct measurement scales and has recently been used to reduce the number of items in other questionnaires. In the present study, CSI-9 had acceptable internal consistency.

Table 6. Exploratory factor analyses using ESEM.

|                | CFI    | SRMR  | AIC          | BIC          | RMSEA  |
|----------------|--------|-------|--------------|--------------|--------|
| CSI-25         |        |       |              |              |        |
| One-factor     | 0.796  | 0.057 | 31501.483    | 31818.325    | 0.073  |
| Two-factor     | 0.864  | 0.048 | 31278.427    | 31696.658    | 0.063  |
| Three-factor   | 0.914  | 0.037 | 31118.771    | 31634.167    | 0.052  |
| Four-factor    | 0.940  | 0.031 | 31043.022    | 31651.358    | 0.046  |
| Five-factor    | 0.952  | 0.028 | 31021.255    | 31718.307    | 0.043  |
| CSI-9          |        |       |              |              |        |
| One-factor     | 0.868  | 0.056 | 12264.962    | 12379.025    | 0.102  |
| Two-factor     | 0.942  | 0.034 | 12192.360    | 12340.220    | 0.081  |

ESEM: Exploratory Structural Equation Modeling, CFI: Comparative Fit Index, RMSEA: Root Mean Square Error of Approximation, SRMR: Standardized Root Mean Square Residual, AIC: Akaike Information Criterion, BIC: Bayesian information criterion

https://doi.org/10.1371/journal.pone.0200152.t006
unidimensional attributes, no notable DIF, test–retest reliability, and was functional on the category rating scale. Overall, CSI-9 showed adequate psychometric properties for use in evaluating health symptoms related to CSS in patients with musculoskeletal pain disorders. Therefore, CSI-9 might be useful in treatment planning when a shortened version of a questionnaire is needed, such as in a time-limited situation or for a specific population.

As result of Rasch analysis, 9 items were selected. The face validity of the CSI-9 items is very good. For instance, the items correspond very well with the current criteria for fibromyalgia, using the Widespread Pain Index [63] and Symptom Severity Score, which assesses widespread pain distribution, fatigue, unrefreshed sleep, and cognitive symptoms.

The average person endorsability of CSI-25 and CSI-9 were -1.42 logits and -1.09 logits, respectively. Both versions covered average and high levels of somatic and emotional symptoms related to central CSS and are therefore best suited for use with people who have health symptoms related to CSS.

Rating categories complied with the set criteria for category functioning and step measures endorsed monotonically from easy to hard across category responses, supporting proper category order in CSI-9.

Although PCA analysis of the residuals of CSI-25 suggests the presence of a second dimension (eigenvalue > 2.0), CSI-9 has unidimensional attributes (eigenvalue < 2.0). This result supports the notion that CSI-9 is appropriate with respect to Rasch analysis. Therefore, a meaningful comparison of CS across patients should be conducted using CSI-9.

The internal consistency of CSI-9 was noteworthy (Cronbach's alpha of 0.80) and aligned well with the original English version (Cronbach's alpha of 0.87) [7] and Japanese version (Cronbach’s alpha of 0.89). In general, as the number of items in the questionnaire increases, so does the superiority of the value of Cronbach’s alpha. Therefore, Cronbach’s alpha of CSI-9

Table 7. Correlation between the original CSI, the short form of the CSI, and the clinical variables.

|                          | Original (CSI-25) | Short form (CSI-9) |
|--------------------------|-------------------|-------------------|
| Original (25-item)       | -                 | 0.91*             |
| Pain intensity           | 0.42*             | 0.45*             |
| Pain interference        | 0.51*             | 0.50*             |
| EQ-5D                    | -0.43*            | -0.41*            |

* Indicates p < 0.001

https://doi.org/10.1371/journal.pone.0200152.t007

Table 8. Comparisons between clinical variables grouped based on the CSI-9 severity.

| Subclinical 0–9       | Mild 10–19 | Moderate/Severe 20–36 | ANOVA or Chi-squared P-value | Effect size |
|-----------------------|------------|-----------------------|-----------------------------|-------------|
| N = 223               | N = 240    | N = 42                |                             |             |
| Age                   |            |                       |                             |             |
| 52.8 (15.6)           | 53.1 (14.6) | 46.4 (13.6)           | 0.02                        | 0.15        |
| Female (%)            |            |                       |                             |             |
| 129 (57.8) *          | 174 (72.5) †| 30 (71.4)             | 0.003                       | 0.14        |
| Pain duration (weeks) |            |                       |                             |             |
| 15.2 (35.1) †         | 24.4 (56.8) | 51 (118.3) †          | 0.001                       | 0.16        |
| Pain intensity        |            |                       |                             |             |
| 2.3 (1.4) †           | 3.3 (1.7) † | 4.4 (1.9) †           | < 0.001                     | 0.40        |
| Pain interference     |            |                       |                             |             |
| 1.6 (1.5) †           | 2.9 (2.1) † | 4.8 (2.4) †           | < 0.001                     | 0.49        |
| EQ-5D                 |            |                       |                             |             |
| 0.74 (0.11) †         | 0.70 (0.11) †| 0.60 (0.11) †         | < 0.001                     | 0.35        |

Post-hoc differences between severity-level groups are indicated via superscript number.

* Male > Female
† Female > Male

Standard deviations or percentage female in parentheses

https://doi.org/10.1371/journal.pone.0200152.t008

Table 7. Correlation between the original CSI, the short form of the CSI, and the clinical variables.

|                          | Original (CSI-25) | Short form (CSI-9) |
|--------------------------|-------------------|-------------------|
| Original (25-item)       | -                 | 0.91*             |
| Pain intensity           | 0.42*             | 0.45*             |
| Pain interference        | 0.51*             | 0.50*             |
| EQ-5D                    | -0.43*            | -0.41*            |

* Indicates p < 0.001

https://doi.org/10.1371/journal.pone.0200152.t007

Table 8. Comparisons between clinical variables grouped based on the CSI-9 severity.

| Subclinical 0–9       | Mild 10–19 | Moderate/Severe 20–36 | ANOVA or Chi-squared P-value | Effect size |
|-----------------------|------------|-----------------------|-----------------------------|-------------|
| N = 223               | N = 240    | N = 42                |                             |             |
| Age                   |            |                       |                             |             |
| 52.8 (15.6)           | 53.1 (14.6) | 46.4 (13.6)           | 0.02                        | 0.15        |
| Female (%)            |            |                       |                             |             |
| 129 (57.8) *          | 174 (72.5) †| 30 (71.4)             | 0.003                       | 0.14        |
| Pain duration (weeks) |            |                       |                             |             |
| 15.2 (35.1) †         | 24.4 (56.8) | 51 (118.3) †          | 0.001                       | 0.16        |
| Pain intensity        |            |                       |                             |             |
| 2.3 (1.4) †           | 3.3 (1.7) † | 4.4 (1.9) †           | < 0.001                     | 0.40        |
| Pain interference     |            |                       |                             |             |
| 1.6 (1.5) †           | 2.9 (2.1) † | 4.8 (2.4) †           | < 0.001                     | 0.49        |
| EQ-5D                 |            |                       |                             |             |
| 0.74 (0.11) †         | 0.70 (0.11) †| 0.60 (0.11) †         | < 0.001                     | 0.35        |

Post-hoc differences between severity-level groups are indicated via superscript number.

* Male > Female
† Female > Male

Standard deviations or percentage female in parentheses

https://doi.org/10.1371/journal.pone.0200152.t008
is lower than that of CSI-25. In addition, the ICC score was 0.79 (95% CI 0.71–0.85), indicating that CSI-9 had excellent reliability.

CSI-9 adequately comprises all five components of CSS (emotional distress = item 15, urological and general symptom = items 9 and 23, muscle symptom = items 2 and 18, headache/jaw symptoms = item 10, sleep disturbance = items 1 and 12, and not loading = item 13) in the Japanese version [21]. Therefore, CSI-9 could cover a wide range of CSS in the Japanese version.

For a satisfactory short form, the reduction in the correlation scores of the short form should not drop by more than 0.10 from the original version [24]. Our results met this requirement by showing equivalence between CSI-25 and CSI-9 scores. In addition, the ICC of the CSI-25 and CSI-9 was 0.69, suggesting substantial agreement, thereby making CSI-9 a promising measure.

In the present study, patients were divided into subgroups according to the number of CSS diagnosis. The CSI-9 total score in patients with no CSS was lower than that in patients with 1, 2, and 3 or more CSS, but there was no difference in the CSI-9 total score between participants with 1 and 2 CSS. Therefore, we determined three levels of severity in CSI-9, which included subclinical (0–9), mild (10–19), and moderate/severe (20–36). The study results suggest that a strong relationship exists between the CSI severity groups and pain intensity, disability, and health-related QOL. The lowest CSI severity group reported lower pain intensity, disability, and health-related QOL, whereas the highest CSI severity group reported higher pain intensity, disability, and health-related QOL. These results suggest that the CSI severity groups in CSI-9 have high concurrent and construct validity. Therefore, clinically relevant symptom severity levels provide more useful information to healthcare providers in assessing CS/CSS-related symptoms.

Our results are not intended to suggest abandoning CSI-25. CSI-25 (original version) has been psychometrically validated in many languages, and its dimensionality and reliability have been established, suggesting that CSI could detect comprehensive traits of CS. The CSI-9 would be a valid and reliable option if researchers or clinicians want to use an abbreviated measure of CSS-related symptoms, such as screening to rule out a disorder or epidemiological surveys.

There were several limitations to our study. First, our study included individuals between the age of 20 and 80 years. Therefore, it is possible that age, sex, pain intensity, and pain duration influenced the results of psychometric properties. However, a notable DIF was not found for any of the items in CSI-9, suggesting that there is no effect of participant age, sex, or pain intensity and duration. This finding indicates that these factors might not affect the model. Second, this study included a convenience sample of participants with musculoskeletal disorders who were recruited from a single clinic. Future studies, in which data is compared across multiple centers, are warranted to verify the findings of this study. Third, this study utilized a questionnaire that was psychometrically validated in a Japanese sample and therefore validation of the other language version of the short form of CSI is needed. Fourth, the short form of CSI was extracted from one administration of the full CSI. Further research to investigate the specific CSI short form might be required for more definitive conclusions. Fifth, CSS diagnoses were established from the same self-reported instrument as the CSI scores. This procedure is limited as a validation, similar to internal measure based on two different procedures (categorical vs quantitative). Absence of a non-self-reported type and number of clinical diagnosis of CSS is needed in the further study.

**Conclusion**

A nine-item short form of CSI has acceptable psychometric properties and is suitable for use for patients with musculoskeletal pain. Thus, CSI-9 can be used as a brief instrument to evaluate CS.
Supporting information

S1 Table. CSI-25 and CSI-9. (DOCX)

S1 Data. Anonymized data. (ZIP)

Acknowledgments

We thank Yuko Inoue and Yuno Yonezaki for assistance with data collection and data analysis. This study was supported by Health Labour Sciences Research Grant Number 17948489.

Author Contributions

Data curation: Katsuyoshi Tanaka, Akira Mibu, Masahiro Manfuku, Satoko Yono.

Funding acquisition: Tomohiko Nishigami.

Investigation: Tomohiko Nishigami.

Methodology: Tomohiko Nishigami, Akihito Tanabe.

Project administration: Tomohiko Nishigami.

Software: Tomohiko Nishigami.

Writing – original draft: Tomohiko Nishigami.

Writing – review & editing: Tomohiko Nishigami.

References

1. Loeser JD, Treede RD. The Kyoto protocol of IASP Basic Pain Terminology. Pain. 2008; 137: 473–477. https://doi.org/10.1016/j.pain.2008.04.025 PMID: 18583048

2. Lluch E, Torres R, Nijs J, Van Oosterwijck J. Evidence for central sensitization in patients with osteoarthritis pain: a systematic literature review. Eur J Pain. 2014; 18:1367–1375. https://doi.org/10.1002/ej.1532-2149.2014.499.x PMID: 24700605

3. Noten S, Struyf F, Lluch E, D’Hoore M, Van Looveren E, Meeus M. Central Pain Processing in Patients with Shoulder Pain: A Review of the Literature. Pain Pract. 2017; 17:267–280. https://doi.org/10.1111/papr.12502 PMID: 27739242

4. Van Oosterwijck J, Nijs J, Meeus M, Paul L. Evidence for central sensitization in chronic whiplash: a systematic literature review. Eur J Pain. 2013; 17:299–312. https://doi.org/10.1002/j.1532-2149.2012.00193.x PMID: 23008191

5. Cagnie B, Coppieters I, Dencker S, Six J, Danneels L, Meeus M. Central sensitization in fibromyalgia? A systematic review on structural and functional brain MRI. Semin Arthritis Rheum. 2014; 44:68–75. https://doi.org/10.1016/j.semarthrit.2014.01.001 PMID: 24508406

6. Plinsinga ML, Brink MS, Vicenzino B, van Wilgen CP. Evidence of Nervous System Sensitization in Commonly Presenting and Persistent Painful Tendinopathies: A Systematic Review. J Orthop Sports Phys Ther. 2015; 45:864–875. https://doi.org/10.2519/jospt.2015.5895 PMID: 26390275

7. Mayer TG, Neblett R, Cohen H, Howard KJ, Choi YH, Williams MJ, P, et al. The development and psychometric validation of the central sensitization inventory. Pain Pract. 2012; 12:276–285. https://doi.org/10.1111/j.1533-2500.2011.00493.x PMID: 21951710

8. Cuesta-Vargas Al, Neblett R, Ciarotto A, Kregel J, Nijs J, van Wilgen CP, et al. Dimensionality and Reliability of the Central Sensitization Inventory in a Pooled Multicountry Sample. J Pain. 2018; 19:317–329. https://doi.org/10.1016/j.jpain.2017.11.006 PMID: 29199933

9. Neblett R, Cohen H, Choi Y, Hartzell MM, Williams M, Mayer TG, et al. The central sensitization inventory (CSI): establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample. J Pain. 2013; 14:438–445. https://doi.org/10.1016/j.jpain.2012.11.012 PMID: 23490634
28. Tan G, Nguyen Q, Cardin SA, Jensen MF. Validating the use of two-item measures of pain beliefs and coping strategies for a veteran population. J Pain. 2006; 7:252–260. https://doi.org/10.1016/j.jpain.2005.11.007 PMID: 16618469

27. Riddle DL, Jensen MP. Construct and criterion-related validity of brief pain coping scales in persons with chronic knee osteoarthritis pain. Pain Med. 2013; 14:265–275. https://doi.org/10.1111/pme.12007 PMID: 2340934

26. Jensen M, Keefe FJ, Lefevre JC, Romano JM, Turner JA. One- and two-item measures of pain beliefs and coping strategies. Pain. 2003; 104:453–469. PMID: 12927618

25. Knezevic A, Neblett R, Jeremic-Knezevic M, Tomasevic-Todorovic S, Boskovic K, Colovic P, et al. Cross cultural adaptation and validity of the Serbian version of the Central Sensitization Inventory in patients with musculoskeletal disorders. PLoS One. 2017; 12:e0188719. https://doi.org/10.1371/journal.pone.0188719 PMID: 29216211

24. McWilliams LA, Kowal J, Wilson KG. Development and evaluation of short forms of the Pain Catastrophizing Scale and the pain self-efficacy questionnaire. Eur J Pain 2015; 19:1342–1349. https://doi.org/10.1002/ejp.665 PMID: 25766681

23. Scerbo T, Colasurdo J, Dunn S, Unger J, Nijs J, Cook C. Measurement Properties of the Central Sensitization Inventory: A Systematic Review. Pain Pract. 2018; 18:463–472. https://doi.org/10.1111/papr.12618 PMID: 28777895

22. Scretta T, Colosurdo J, Dunn S, Unger J, Nijs J, Cook C. Measurement Properties of the Central Sensitization Inventory. Clin J Pain. 2016; 32:624–630. https://doi.org/10.1097/AJP.0000000000000306 PMID: 26418360

21. Cuesta-Vargas AI, Roldan-Jimenez C, Neblett R, Gatchel RJ. Cross-cultural adaptation and validity of the Spanish central sensitization inventory. Springerplus. 2016; 5:1837. https://doi.org/10.1186/s40064-016-3515-4 PMID: 27818875

20. Bid Dibyendunarayan D, Sonni Neela C, Rathod Priyanshu V, A Thangamani Ramalingam. Content Validity and Test-Retest Reliability of the Gujarati Version of the Central Sensitization Inventory. National Journal of Integrated Research in Medicine. 2016; 7:18–24.

19. Knezevic A, Neblett R, Jeremic-Knezevic M, Tomasevic-Todorovic S, Boskovic K, Colovic P, et al. Cross cultural adaptation and psychometric validation of the Serbian version of the Central Sensitization Inventory (CSI). Pain Pract. 2016; 16:463–472. https://doi.org/10.1111/papr.12311 PMID: 25980527

18. Bennett EE, Walsh KM, Thompson NR, Krishnaney AA. Central Sensitization Inventory as a Predictor of Worse Quality of Life Measures and Increased Length of Stay Following Spinal Fusion. World Neurosurg. 2017; 104:594–600. https://doi.org/10.1016/j.wneu.2017.04.166 PMID: 28479522

17. Neblett R, Hartzell MM, Cohen H, Mayer TG, Williams M, Choi Y, et al. Ability of the central sensitization inventory to identify central sensitivity syndromes in an outpatient chronic pain sample. Clin J Pain 2015; 31:323–332. https://doi.org/10.1097/AJP.0000000000000113 PMID: 24806467

16. Neblett R, Hartzell MM, Williams M, Bevers KR, Mayer TG, Gatchel RJ. Use of the Central Sensitization Inventory (CSI) as a treatment outcome measure for patients with chronic spinal pain disorder in a functional restoration program. Spine J. 2017; 17:1819–1829. https://doi.org/10.1016/j.spinee.2017.06.008 PMID: 28619687

15. Kregel J, Vuijk PJ, Descheemaeker F, Keizer D, van der Noord R, Nijs J, et al. The Dutch Central Sensitization Inventory (CSI): Factor Analysis, Discriminative Power and Test-Retest Reliability. Clin J Pain. 2016; 32:624–630. https://doi.org/10.1097/AJP.0000000000000306 PMID: 26418360

14. Kim SH, Yoon KB, Yoon DM, Yoo JH, Ahn KR. Influence of Centrally Mediated Symptoms on Postoperative Pain in Osteoarthritis Patients Undergoing Total Knee Arthroplasty: A Prospective Observational Evaluation. Pain Pract. 2015; 15:E46–53. https://doi.org/10.1111/papr.12311 PMID: 25980527

13. Trang T, Beggs S, Salter MW. Brain-derived neurotrophic factor from microglia: a molecular substrate for neuropathic pain. Neuron Glia Biol. 2011; 7:99–108. https://doi.org/10.1016/S1740925X12000087 PMID: 22613083

12. Caumo W, Antunes LC, Elk fury JL, Herbstreth EG, Busanello Simmann R, Souza A, et al. The Central Sensitization Inventory validated and adapted for a Brazilian population: psychometric properties and its relationship with brain-derived neurotrophic factor. J Pain Res. 2017; 10:2109–2122. https://doi.org/10.2147/JPR.S131479 PMID: 28979158

11. Neblett R, Hartzell MM, Williams M, Bevers KR, Mayer TG, Gatchel RJ. Use of the Central Sensitization Inventory (CSI) as a treatment outcome measure for patients with chronic spinal pain disorder in a functional restoration program. Spine J. 2017; 17:1819–1829. https://doi.org/10.1016/j.spinee.2017.06.008 PMID: 28619687

10. Neblett R, Hartzell MM, Cohen H, Mayer TG, Williams M, Choi Y, et al. Ability of the central sensitization inventory to identify central sensitivity syndromes in an outpatient chronic pain sample. Clin J Pain 2015; 31:323–332. https://doi.org/10.1097/AJP.0000000000000113 PMID: 24806467

9. Caumo W, Antunes LC, Elk fury JL, Herbstreth EG, Busanello Simmann R, Souza A, et al. The Central Sensitization Inventory validated and adapted for a Brazilian population: psychometric properties and its relationship with brain-derived neurotrophic factor. J Pain Res. 2017; 10:2109–2122. https://doi.org/10.2147/JPR.S131479 PMID: 28979158

8. Trang T, Beggs S, Salter MW. Brain-derived neurotrophic factor from microglia: a molecular substrate for neuropathic pain. Neuron Glia Biol. 2011; 7:99–108. https://doi.org/10.1016/S1740925X12000087 PMID: 22613083

7. McWilliams LA, Kowal J, Wilson KG. Development and evaluation of short forms of the Pain Catastrophizing Scale and the pain self-efficacy questionnaire. Eur J Pain 2015; 19:1342–1349. https://doi.org/10.1002/ejp.665 PMID: 25766681

6. Nishigami T, Mibu A, Tanaka K, Yamashita Y, Watanabe A, Tanabe A. Psychometric properties of the Japanese version of short forms of the Pain Catastrophizing Scale in participants with musculoskeletal pain: A cross-sectional study. J Orthop Sci. 2017; 22:351–356. https://doi.org/10.1016/j.jos.2016.11.015 PMID: 28097217

5. Jensen M, Keefe FJ, Lefevre JC, Romano JM, Turner JA. One- and two-item measures of pain beliefs and coping strategies. Pain. 2003; 104:453–469. PMID: 12927618

4. Bid Dibyendunarayan D, Sonni Neela C, Rathod Priyanshu V, A Thangamani Ramalingam. Content Validity and Test-Retest Reliability of the Gujarati Version of the Central Sensitization Inventory. National Journal of Integrated Research in Medicine. 2016; 7:18–24.

3. Bennett EE, Walsh KM, Thompson NR, Krishnaney AA. Central Sensitization Inventory as a Predictor of Worse Quality of Life Measures and Increased Length of Stay Following Spinal Fusion. World Neurosurg. 2017; 104:594–600. https://doi.org/10.1016/j.wneu.2017.04.166 PMID: 28479522

2. Caumo W, Antunes LC, Elk fury JL, Herbstreth EG, Busanello Simmann R, Souza A, et al. The Central Sensitization Inventory validated and adapted for a Brazilian population: psychometric properties and its relationship with brain-derived neurotrophic factor. J Pain Res. 2017; 10:2109–2122. https://doi.org/10.2147/JPR.S131479 PMID: 28979158

1. Caumo W, Antunes LC, Elk fury JL, Herbstreth EG, Busanello Simmann R, Souza A, et al. The Central Sensitization Inventory validated and adapted for a Brazilian population: psychometric properties and its relationship with brain-derived neurotrophic factor. J Pain Res. 2017; 10:2109–2122. https://doi.org/10.2147/JPR.S131479 PMID: 28979158
29. Nicholas MK, McGuire BE, Asghari A. A 2-item short form of the Pain Self-efficacy Questionnaire: development and psychometric evaluation of PSEQ-2. J Pain. 2015; 16:153–163. https://doi.org/10.1016/j.jpain.2014.11.002 PMID: 25463701

30. Rasch G. Probabilistic Models for Some Intelligence and Attainment Tests. Chicago, IL: University of Chicago; 1960.

31. Alcalá MJ, Casellas F, Fontanet G, Prieto L, Malagelada JR. Shortened questionnaire on quality of life for inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10:383–391. PMID: 15475746

32. Marella M, Busija L, Islam FM, Devine A, Fotis K, Baker SM, et al. Field-testing of the rapid assessment of disability questionnaire. BMC Public Health. 2014; 14:940. https://doi.org/10.1186/1471-2458-14-900 PMID: 25179800

33. Ustün TB, Chatterji S, Kostanjsek N, Rehm J, Kennedy C, Epping-Jordan J, et al. Developing the World Health Organization Disability Assessment Schedule 2.0. Bull World Health Organ. 2010; 88:815–823 https://doi.org/10.2471/BLT.09.067231 PMID: 21076562

34. Bilbao A, Quintana JM, Escobar A, Las Hayas C, Orive M, et al. Validation of a proposed WOMAC short form for patients with hip osteoarthritis. Health Qual Life Outcomes. 2011; 9:75. https://doi.org/10.1186/1477-7525-9-75 PMID: 21936886

35. Vergara M, Sicilia B, Prieto L, Casellas F, Ramos A, Gomollón F, et al. Development and Validation of the Short Crohn’s Disease Work Disability Questionnaire. Inflamm Bowel Dis. 2016; 22:955–962. https://doi.org/10.1097/MIB.0000000000000678 PMID: 26933747

36. Wright BD, Stone MH: Best Test Design: Rasch Measurement Chicago: MESA Press; 1979.

37. Wright BD, Masters GN: Rating Scale Analysis Chicago: MESA Press; 1982.

38. Wright BD, Masters GN: Rating Scale Analysis Chicago: MESA Press; 1982.

39. EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990; 16:199–208. PMID: 10109801

40. Rabin R, de Charron F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001; 33:337–343. PMID: 11491192

41. Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002; 11:341–353. https://doi.org/10.1002/hec.673 PMID: 12007165

42. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994; 23:129–138. PMID: 8080219

43. Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F. A brief cancer pain assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory—BPI-J. J Pain Symptom Manage. 1998; 16:364–373. PMID: 9879161

44. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain. 2004; 20:309–318. PMID: 15322437

45. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMPACT Recommendations. J Pain. 2008; 9:105–121. https://doi.org/10.1016/j.jpain.2007.09.005 PMID: 1805266

46. Mendoza TR, Koyyalagunta D, Burton AW, Thomas SK, Phan MH, Giralt SA, et al. Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treat with kyphoplasty or vertebroplasty. J Pain. 2012; 13:564–570. https://doi.org/10.1016/j.jpain.2012.03.003 PMID: 22543044

47. Wright BD, Masters GN. Rating Scale Analysis. Chicago, IL: MESA Press; 1982.

48. Wright BD, Linacre JM. Reasonable mean-square fit values. Rasch Meas Transac. 1994; 8:370.

49. Jafari P, Bagheri Z, Ayatollahi SMT, Soltani Z. Using Rasch rating scale model to reassess the psychometric properties of the Persian version of the PedSQLTM 4.0 Generic Core Scales in school children. Health Qual Life Outcomes. 2012; 10:27. https://doi.org/10.1186/1477-7525-10-27 PMID: 22414135

50. Kook SH, Varni JW. Validation of the Korean version of the pediatric quality of life inventory™ 4.0 (PedSQL™) generic core scales in school children and adolescents using the Rasch model. Health Qual Life Outcomes. 2008; 6:41. https://doi.org/10.1186/1477-7525-6-41 PMID: 18518951

51. Cronbach LJ, Shavelson RJ. My current thoughts on coefficient alpha and successor procedures. Educ Psychol Measur. 2004; 64:391–418.

52. Tennant A, Conaghan PG. The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper? Arthritis Rheum. 2007; 57:1358–1362. https://doi.org/10.1002/art.23108 PMID: 18050173
53. Linacre JM. A User’s Guide to WINSTEPS. Winsteps.com, Chicago, 2005.
54. Ramp M, Khan F, Misajon RA, Pallant JF. Rasch analysis of the Multiple Sclerosis Impact Scale MSIS-29. Health Qual Life Outcomes. 2009; 7:58. https://doi.org/10.1186/1477-7525-7-58 PMID: 19545445
55. Moreton BJ, Walsh DA, Turner KV, Lincoln NB. Rasch analysis of the Chronic Pain Acceptance Questionnaire Revised in people with knee osteoarthritis. J Rehabil Med. 2015; 47:655–661. https://doi.org/10.2340/16501977-1977 PMID: 26035839
56. Browne MW, Cudeck R. Alternative ways of assessing model fit. In Bollen K. A. & Long J. S. (Eds.), Testing structural equation models (pp. 136–162). Newbury Park, CA: Sage., 1993.
57. Hu L T, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling: A Multidisciplinary Journal. 1999; 6:1–55.
58. Weston R, Gore PA. A brief guide to structural equation modeling. The Counseling Psychologist. 2006; 34:719–751.
59. Fisher R. A. On the Interpretation of $\chi^2$ from Contingency Tables, and the Calculation of P. J R Statist Soc. 1922; 85:87–94.
60. Hungi N. Employing the Rasch model to detect biased items. In: Alagumalai S, Curtis D, Hungi N, eds. Applied Rasch Measurement: A Book of Exemplars. Dordrecht, Germany: Springer; 2005.
61. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33:159–174. PMID: 843571
62. Neblett R, Hartzell MM, Mayer TG, Cohen H, Gatchel RJ. Establishing Clinically Relevant Severity Levels for the Central Sensitization Inventory. Pain Pract. 2017; 17:166–175. https://doi.org/10.1111/papr.12449 PMID: 26989894
63. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010; 62:600–10.